Comparative Pharmacology
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus HISPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus HISPRIL.
CLEMASTINE FUMARATE vs HISPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clemastine fumarate is a competitive antagonist of histamine at H1-receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and pruritus. It also exhibits anticholinergic and sedative effects.
HISPRIL (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and afterload.
1.34 mg orally twice daily; max 8.04 mg/day
10 mg orally once daily, increased to 20 mg once daily after 2-4 weeks if needed.
None Documented
None Documented
Terminal elimination half-life: 21 ± 6 hours. Provides sustained antihistamine effect, allowing twice-daily dosing.
The terminal elimination half-life of HISPRIL is approximately 12-15 hours in patients with normal renal function, supporting twice-daily dosing. In moderate to severe renal impairment (CrCl <30 mL/min), half-life is prolonged up to 30-40 hours, necessitating dose interval adjustment.
Primarily renal (45-55% as unchanged drug and metabolites) and fecal (30-40%), with biliary excretion contributing minorly.
HISPRIL is predominantly excreted renally, with approximately 60-70% of an administered dose recovered unchanged in urine over 48 hours. Hepatic metabolism accounts for <10% of elimination, and fecal excretion contributes <5%.
Category C
Category C
Antihistamine
Antihistamine